Related Experiment Video
Updated: Dec 15, 2025

The WATCHMAN Left Atrial Appendage Closure Device for Atrial Fibrillation
Published on: February 28, 2012
Should We Reintroduce Previous Venous Thromboembolism Into Decision-Making for Anticoagulation in Atrial
Thure Filskov Overvad1, Flemming Skjøth2, Ida Ehlers Albertsen3
1Aalborg Thrombosis Research Unit, Department of Clinical Medicine, Faculty of Health, Aalborg University, Denmark; Department of Medicine, North Denmark Regional Hospital, Hjørring, Denmark.
Insights
History of venous thromboembolism (VTE) did not increase stroke risk in atrial fibrillation patients. However, a prior VTE history indicates a higher overall risk for future thromboembolic events, including VTE itself.
Area of Science:
- Cardiology
- Hematology
- Epidemiology
Background:
- Atrial fibrillation (AF) is a major risk factor for thromboembolic events.
- The prognostic significance of a prior history of venous thromboembolism (VTE) in AF patients remains unclear.
Purpose of the Study:
- To determine if a history of VTE impacts the risk of future thromboembolic events in patients diagnosed with atrial fibrillation.
Main Methods:
- Nationwide cohort study (2000-2017) using Danish health registries.
- Included 246,313 patients with incident atrial fibrillation.
- Cox regression analyses adjusted for CHA₂DS₂-VASc score components and oral anticoagulation use.
Main Results:
- Patients with prior VTE had a similar adjusted risk for ischemic stroke or systemic embolism (HR 0.99; 95% CI, 0.90-1.09).
- Patients with prior VTE faced a significantly higher risk for a composite outcome including VTE (HR 1.76; 95% CI, 1.64-1.90).
- Findings were consistent across VTE subtypes, low CHA₂DS₂-VASc scores, and non-anticoagulated patients.
Conclusions:
- Prior VTE history does not elevate stroke risk in AF patients.
- Individuals with AF and prior VTE represent a high-risk group due to increased risk of future VTE.
- This risk stratification is crucial for oral anticoagulation decision-making in AF patients.
Background:
We aimed to investigate whether history of venous thromboembolism should be considered a prognostic factor for future thromboembolic events in patients with atrial fibrillation.
Methods:
This was a nationwide cohort study of patients with incident atrial fibrillation from 2000-2017, defined and characterized using Danish health registries. Cox regression analyses were used to calculate hazard ratios and 95% confidence intervals for the outcomes ischemic stroke or systemic embolism, and ischemic stroke, systemic embolism, or venous thromboembolism, according to history of venous thromboembolism. Analyses were adjusted for components of the CHA2DS2-VASc score and time-varying use of oral anticoagulation.
Results:
The study included 246,313 patients with incident atrial fibrillation, of which 6,516 (2.6%) had previous venous thromboembolism. Patients with previous venous thromboembolism carried an overall similar adjusted risk of ischemic stroke or systemic embolism compared with patients without previous venous thromboembolism (reference; hazard ratio 0.99; 95% confidence interval, 0.90-1.09). When analyzing a composite thromboembolic outcome of ischemic stroke, systemic embolism, or venous thromboembolism, patients with previous venous thromboembolism were at high-risk (hazard ratio 1.76; 95% confidence interval, 1.64-1.90). Similar conclusions were drawn when stratifying by venous thromboembolism subtype, and when restricting to patients with low CHA2DS2-VASc scores or the non-anticoagulated subset of the study population.
Conclusion:
Patients with atrial fibrillation and previous venous thromboembolism carried similar risk of ischemic stroke or systemic embolism compared with patients with atrial fibrillation without previous venous thromboembolism. Nonetheless, patients with previous venous thromboembolism remain a high-risk population due to an excess risk of future venous thromboembolism. Patients and physicians should keep this excess thromboembolic risk in mind when weighing the expected risks and benefits of oral anticoagulation in patients with atrial fibrillation.
More Related Videos
Related Concept Videos
Venous Thrombosis III: Interprofessional Care
Anticoagulant Drugs: Low-Molecular-Weight Heparins
Venous Thrombosis I: Introduction
Anticoagulant Drugs: Vitamin K Antagonists and Direct Oral Anticoagulants
Warfarin, a prominent vitamin K antagonist family member, exerts its effect by inhibiting the enzyme VKORC1 (vitamin K epoxide reductase complex 1). By hindering this enzyme, warfarin...
Venous Thrombosis IV: Nursing Management
Venous Thrombosis II: Clinical Manifestations and Diagnostic Studies

